Jennifer Wellman
About Jennifer Wellman
Jennifer Wellman is the Chief Development Officer with twenty years of experience in AAV vector gene therapy, known for leading the development of Luxturna®, the first FDA-approved gene therapy for a genetic disease.
Chief Development Officer Jennifer Wellman
Jennifer Wellman is the Chief Development Officer with a profound background in adeno-associated viral (AAV) vector gene therapy research and development. She brings twenty years of expertise to her current role, significantly contributing to advancements in gene therapy solutions.
Jennifer Wellman's Education and Expertise in Gene Therapy
Jennifer Wellman holds an Honours B.S. in Microbiology and Immunology from Queen's University in Canada, and she earned an M.S. from the University of New Haven. Her extensive education laid a strong foundation for her specialized expertise in AAV vector gene therapy and has been integral to her career development.
Jennifer Wellman's Role at Spark Therapeutics
Jennifer Wellman co-founded Spark Therapeutics, Inc., where she served as the Head of Product Development Strategy. At Spark Therapeutics, she led the regulatory and clinical development for several AAV gene therapies. Notably, she worked on Luxturna®, the first FDA-approved gene therapy for a genetic disease.
Jennifer Wellman’s Career at Avigen, Inc.
Before her role at Spark Therapeutics, Jennifer Wellman was an Associate Scientist at Avigen, Inc. Avigen was an early clinical-stage AAV gene therapy company, where she gained crucial experience in the foundational phases of gene therapy research and development.